|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ch. 17
|
|
|
|
|
|
2000 LAWS OF MARYLAND
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) RETENTION OF HIGH QUALITY FACULTY, INCLUDING CLINICIANS
AND RESEARCHERS, WHO CONTRIBUTE TO A COMMUNITY FOCUSED CANCER
PROGRAM; AND
(3) CANCER SURVEILLANCE AND EPIDEMIOLOGY, INCLUDING;
(I) DEVELOPMENT OF A COMPREHENSIVE LIST OF
CANCER CAUSING AGENTS;
(II) COMPILATION AND MAPPING OF SOURCES OF EXPOSURE;
(III) A FOCUS ON THE UNIQUE CULTURAL AND OTHER FACTORS
RELATED TO DELAYS IN TREATMENT AND LACK OF ACCESS TO CARE AND
TREATMENT IN UNDERSERVED URBAN AND RURAL COMMUNITIES; AND
(IV) IMPROVED UNDERSTANDING OF CANCER RISK FACTORS AND
HOW THEY IMPACT MARYLAND'S UNIQUE CANCER STATISTICS.
(B) NO MORE THAN TWO THIRDS OF A STATEWIDE ACADEMIC HEALTH
CENTER GRANT AWARDED TO THE JOHNS HOPKINS GROUP INSTITUTIONS MAY BE
EXPENDED ON THE RECRUITMENT AND RETENTION OF FACULTY FOR THE
PURPOSES ESTABLISHED IN SUBSECTION (A) (1) AND (2) OF THIS SECTION.
(C) THE DEPARTMENT SHALL ENHANCE THE MARYLAND CANCER REGISTRY
WITH THE INFORMATION RECEIVED FROM THE JOHNS HOPKINS GROUP
INSTITUTIONS UNDER SUBSECTION (A)(3) OF THIS SECTION.
(D) BEFORE RECEIVING A STATEWIDE ACADEMIC HEALTH CENTER GRANT,
THE JOHNS HOPKINS GROUP INSTITUTIONS SHALL;
(1) SUBMIT A PLAN THAT;
(I) PROVIDES A DETAILED PLAN AS TO HOW THE GRANT WILL BE
SPENT;
(II) TO THE EXTENT PRACTICABLE, PROVIDES A COMPLETE
INVENTORY OF ALL ACTIVITIES RELATING TO RECRUITMENT AND RETENTION OF
FACULTY AND CANCER SURVEILLANCE AND EPIDEMIOLOGY THAT ARE CURRENTLY
BEING CONDUCTED BY THE INSTITUTION, INCLUDING A BREAKDOWN OF THE TYPES
OF CANCER TO WHICH THE ACTIVITIES RELATE;
(III) SPECIFIES THE SOURCE AND AMOUNT OF FUNDING FOR ALL
OF THE CANCER ACTIVITIES IDENTIFIED UNDER ITEM (II) OF THIS PARAGRAPH;
(IV) DEMONSTRATES THAT ANY EARLY DETECTION OR SCREENING
PROGRAM THAT IS OR WILL BE FUNDED UNDER THE STATEWIDE ACADEMIC HEALTH
CENTER GRANT PROVIDES LINKAGES TO NECESSARY TREATMENT, INCLUDING
LOCAL HOSPITALS, COMMUNITY CLINICS, PHYSICIANS, AND OTHER HEALTH CARE
PROVIDERS FOR INDIVIDUALS WHO:
1- ARE DIAGNOSED WITH A TARGETED OR NONTARGETED
CANCER; AND
|
|
|
|
|
|
|
|
|
|
- 232 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
